Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.
Adverse reactions were generally similar to those in other patients receiving Keytruda and chemotherapy, said Merck. "We're pleased to offer a new first-line treatment option for adult patients ...